图书简介
Overcoming Obstacles in Drug Discovery and Development uses real-world case studies to illustrate how critical thinking and problem solving skills are applied in the discovery and development of drugs. It also shows how developing critical thinking to overcome issues plays an essential role in the process. Modern drug discovery and development is a highly complex undertaking that requires scientific and professional expertise to be successful. After the identification of a molecular entity for treating a medical condition, challenges inevitably arise during the subsequent development to understand and characterize the biological profile; feedback from scientists is used to fine-tune the molecular entity to obtain an effective and safe product. In this process, the discovery team may identify unexpected safety issues and new medical disorders for treatment by the molecular entity. Invariably inherent in this complex undertaking are miscues, mistakes, and unexpected problems that can derail development and throw timetables into disarray, potentially leading to failure in the development of a medically useful drug. Addressing critical unexpected problems during development often requires scientists to utilize critical thinking and imaginative problem-solving skills. Overcoming Obstacles in Drug Discovery and Development will be essential to young scientists to help learn the skills to successfully face challenges, learn from mistakes, and further develop critical thinking skills. It will also be beneficial to experienced researchers who can learn from the case studies of successful and unsuccessful drug development.
Preface Kan He, Paul Frederick Hollenberg and Larry C. Wienkers 1. Learning to think critically Brian Barnes 2. Leveraging ADME/PK information to enable knowledge-driven decisions in drug discovery and development Larry C. Wienkers 3. Systems biology and data science in research and translational medicine Karim Azer, Jeff S. Barrett, Mirjam Trame and Cynthia J. Musante 4. Drug Discovery and Development of ASO Brooke Rock 5. Drug development of covalent Inhibitors Upendra P. Dahal and Jan L. Wahlstrom 6. Denosumab: dosing and drug interaction challenges on the path to approval Graham Jang 7. Discovery and development of ADCs: obstacles and opportunities Hsuan Ping Chang, Yuen Kiu Cheung and Dhaval K. Shah 8. How to reduce risk of drug induced liver toxicity from the beginning Jinping Gan, Kan He and W. Griffith Humphreys 9. Optimization for small volume of distribution leading to the discovery of apixaban Kan He 10. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development Simon G. Wong and Shuguang Ma 11. Conquering low oral bioavailability issues in drug discovery and development Timothy J. Carlson 12. Case study of OATP1B DDI assessment and challenges in drug discovery and development-real-life examples Hong Shen, Jinping Gan and Giridhar S. Tirucherai 13. Investigating the link between drug metabolism and toxicity W. Griffith Humphreys 14. Overcoming nephrotoxicity in rats: the successful development and registration of the HIV-AIDS drug efavirenz (Sustiva (R)) D.D. Christ 15. Disproportionate drug metabolites: challenges and solutions Chandra Prakash 16. Disposition and metabolism of ozanimod-Surmounting the unanticipated challenge late in the development Deepak Dalvie and Sekhar Surapaneni 17. Application of reaction phenotyping to address pharmacokinetic variability in patient populations Robert S. Foti, Joseph M. Roesner and Joshua T. Pearson 18. Kyprolis (carfilzomib) (approved): a covalent drug with high extrahepatic clearance via peptidase cleavage and epoxide hydrolysis Zhengping Wang, Jinfu Yang an Christopher Kirk 19. Engaging diversity in research: Does your drug work in overlooked populations? Karen E. Brown and Erica L. Woodahl 20. PBPK modeling for Early clinical study decision making Arian Emami Riedmaier 21. Integrated pharmacokinetic/pharmacodynamic/efficacy analysis in oncology: importance of pharmacodynamic/efficacy relationships Harvey Wong 22. Predicting unpredictable human pharmacokinetics: Case studies from the trenches of drug discovery Zheng Yang 23. Esmolol (soft drug design) Paul W. Erhardt
Trade Policy 买家须知
- 关于产品：
- ● 正版保障：本网站隶属于中国国际图书贸易集团公司，确保所有图书都是100%正版。
- ● 环保纸张：进口图书大多使用的都是环保轻型张，颜色偏黄，重量比较轻。
- ● 毛边版：即书翻页的地方，故意做成了参差不齐的样子，一般为精装版，更具收藏价值。
关于退换货：- 由于预订产品的特殊性，采购订单正式发订后，买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性，发生以下情况的，请直接拒收货物，由快递返回：
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全（例如：光盘等）
并请在工作日通过电话400-008-1110联系我们。
- 签收后，如发生以下情况，请在签收后的5个工作日内联系客服办理退换货：
- ● 缺页/错页/错印/脱线
关于发货时间：- 一般情况下：
- ●【现货】 下单后48小时内由北京（库房）发出快递。
- ●【预订】【预售】下单后国外发货，到货时间预计5-8周左右，店铺默认中通快递，如需顺丰快递邮费到付。
- ● 需要开具发票的客户，发货时间可能在上述基础上再延后1-2个工作日（紧急发票需求，请联系010-68433105/3213）；
- ● 如遇其他特殊原因，对发货时间有影响的，我们会第一时间在网站公告，敬请留意。
关于到货时间：- 由于进口图书入境入库后，都是委托第三方快递发货，所以我们只能保证在规定时间内发出，但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间：- 010-68433105/3213正常接听咨询电话的时间为：周一至周五上午8：30～下午5：00，周六、日及法定节假日休息，将无法接听来电，敬请谅解。
- 其它时间您也可以通过邮件联系我们：customer@readgo.cn,工作日会优先处理。
关于快递：- ● 已付款订单：主要由中通、宅急送负责派送，订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐
